Retrospective study on chemotherapy for advanced biliary tract carcinoma
10.3969/j.issn.1000-8179.2017.09.492
- VernacularTitle:晚期胆系恶性肿瘤化疗方案的回顾性研究
- Author:
Wei KE
;
Xiaochen ZHANG
;
Sufen YU
;
Jing CHEN
;
Xiaoting WANG
;
Mengye HE
;
Jingying PAN
- Keywords:
advanced biliary tract carcinoma;
chemotherapy;
bevacizumab;
overall survival
- From:
Chinese Journal of Clinical Oncology
2017;44(9):429-433
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy of chemotherapy for advanced biliary tract carcinoma and the factors that influence sur-vival. Methods:A total of 91 cases of advanced biliary tract carcinoma from January 2010 to April 2015 were enrolled in our study. The patients' characteristics, chemotherapy regimens, and effects were analyzed. Results:We enrolled 56 males and 35 females with a me-dian age of 57 years. A total of 90 patients were assessable for their responses to first-line chemotherapy. A total of 69 patients re-ceived the GP regimen, whereas 21 patients received some other regimens. The disease control rate (DCR), median progression free survival (mPFS), and median overall survival (mOS) were 68.1%versus 52.4%, 5.10 months versus 2.50 months (P=0.025), and 13.00 months versus 7.20 months, respectively. Only 31 patients received S-1 based regimens, and 12 patients received some other regi-mens as second-line chemotherapy. The DCR, median PFS, and median OS showed no statistical differences. Only four patients re-ceived S-1 based regimen plus bevacizumab as second-line chemotherapy (median PFS 5.3 months;median OS 7 months). Hematologi-call toxicity was the most common side effect in the first-line GP regimen. The side effects of the S-1 based chemotherapy regimen was relatively less. Conclusion:The GP regimen is an effective first-line chemotherapy for advanced biliary tract carcinoma, whereas S-1 ap-pears as an effective second-line chemotherapy drug. Bevacizumab-based regimens may be effective and require further validation.
